Stonepine Capital Management LLC Sells 69,396 Shares of XOMA Co. (NASDAQ:XOMA)

Stonepine Capital Management LLC trimmed its holdings in XOMA Co. (NASDAQ:XOMA - Free Report) by 35.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 125,700 shares of the biotechnology company's stock after selling 69,396 shares during the period. XOMA accounts for about 2.7% of Stonepine Capital Management LLC's investment portfolio, making the stock its 14th largest position. Stonepine Capital Management LLC owned about 1.07% of XOMA worth $3,303,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of XOMA by 238.9% during the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock worth $318,000 after acquiring an additional 8,522 shares during the period. Barclays PLC grew its position in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after buying an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of XOMA during the fourth quarter worth approximately $206,000. Renaissance Technologies LLC grew its position in shares of XOMA by 89.8% during the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company's stock worth $423,000 after buying an additional 7,619 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after purchasing an additional 2,009 shares during the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other XOMA news, CIO Bradley Sitko acquired 4,134 shares of the business's stock in a transaction dated Friday, March 21st. The stock was bought at an average cost of $23.89 per share, with a total value of $98,761.26. Following the completion of the transaction, the executive now directly owns 10,484 shares in the company, valued at approximately $250,462.76. This represents a 65.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of XOMA stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $27.10, for a total value of $10,642,793.30. Following the sale, the insider now directly owns 1,267,545 shares of the company's stock, valued at approximately $34,350,469.50. The trade was a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders acquired 29,312 shares of company stock worth $735,061 over the last ninety days. 7.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

XOMA has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $104.00 target price on shares of XOMA in a research note on Friday, March 28th. StockNews.com raised XOMA from a "sell" rating to a "hold" rating in a research note on Friday, April 11th. Finally, Benchmark initiated coverage on XOMA in a research note on Thursday, April 17th. They issued a "buy" rating and a $35.00 price target on the stock.

XOMA Price Performance

NASDAQ:XOMA traded down $1.48 during trading hours on Wednesday, reaching $25.12. The company had a trading volume of 51,390 shares, compared to its average volume of 30,710. The stock has a 50-day moving average of $22.35 and a two-hundred day moving average of $25.39. XOMA Co. has a one year low of $18.35 and a one year high of $35.00. The firm has a market capitalization of $300.61 million, a PE ratio of -7.22 and a beta of 0.89. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.32. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million. Analysts forecast that XOMA Co. will post -1.41 earnings per share for the current year.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.